肺氣腫治療市場規模、佔有率和成長分析：按治療類型、嚴重程度、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球肺氣腫治療市場價值為 85.2 億美元，預計到 2033 年將從 2025 年的 89.9 億美元成長至 138.5 億美元，預測期（2026-2033 年）的複合年成長率為 5.52%。

全球肺氣腫治療市場以多種療法為特徵，包括藥物、生物製藥和醫療設備，旨在緩解氣流阻塞並維持肺功能。慢性阻塞性肺病(COPD) 的日益流行，加上人口老化和人們對呼吸系統健康日益成長的關注，正在推動對有效療法的需求。從基礎支氣管擴張劑到先進的長效毒蕈鹼受體拮抗劑和生物製藥的演變，反映了臨床治療的顯著進步，不斷改善症狀管理並擴大醫保覆蓋範圍。此外，用於監測患者用藥依從性和肺功能的數位健康平台的興起，透過實現及時干預，減少住院次數並降低整體醫療成本，正在改變整個行業。醫療設備製造商與遠端醫療提供者之間的策略合作，正在進一步加速創新並開闢新的商機。

全球肺氣腫治療市場的成長要素

全球肺氣腫治療市場正顯著擴張，這主要得益於公眾意識的提升以及醫療專業人員推廣計畫的加強，從而提高了疾病的早期檢出率。這種意識的提高促使患者及其看護者尋求及時的治療方案，進而增加了對旨在改善生活品質和延緩疾病進展的有效療法的需求。因此，醫療服務提供者正更加積極地投資於以患者為中心的創新藥物輸送系統和支援服務。此外，患者權益倡導組織的正面影響也推動了先進療法的應用，這些療法旨在滿足未被滿足的需求並最佳化治療效果。

全球肺氣腫治療市場的阻礙因素

先進生物製藥、創新藥物輸送系統和綜合護理方案的高成本給患者、保險公司和醫療機構帶來了巨大的經濟挑戰。通常，不完全的報銷機制會導致治療啟動延遲或患者拒絕治療，從而抑制市場需求，阻礙尖端解決方案的推廣應用，尤其是在醫療資源有限或自付費用對弱勢群體造成沉重負擔的地區。這種情況最終會阻礙整體市場成長。此外，成本效益評估往往更傾向於已上市的學名藥，進一步限制了旨在治療肺氣腫的高階治療方案的市場潛力。

全球肺氣腫治療市場趨勢

在全球肺氣腫治療市場，個人化醫療正日益成為一種趨勢。醫療專業人員擴大利用先進的影像學和基因分析技術，根據患者的個別表現型量身定做治療方案。這種方法提高了支氣管鏡治療和藥物療法的精準度，從而改善了治療效果並減少了副作用。隨著關注點轉向整合呼吸內科、放射科和復健科的多學科診療路徑，臨床醫生之間的協作決策也得到了推廣。同時，隨著報銷模式轉向基於結果的框架，醫院正在增加對必要培訓和技術的投資，從而推動了成熟市場和新興市場對以患者為中心的創新解決方案的需求。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球肺氣腫治療市場規模：依治療類型分類

• 支氣管擴張劑
• 皮質類固醇
• 支氣管瓣膜
• 肺減容手術
• 氧氣療法

全球肺氣腫治療市場規模：依嚴重程度分類

• 輕度至中度
• 嚴重

全球肺氣腫治療市場規模：依通路分類

• 醫院藥房
• 零售藥房

全球肺氣腫治療市場規模：依最終用戶分類

• 呼吸系統醫療設備
• 醫院

全球肺氣腫治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AstraZeneca（Symbicort）
• GlaxoSmithKline
• Boehringer Ingelheim（Spiriva）
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical
• PulmonX Corporation
• Olympus Corporation
• Boston Scientific（Spiration Valve）
• BTG plc（Boston Scientific）
• Uptake Medical
• Broncus Medical
• Nuvaira Inc.
• CSA Medical
• Spiration（Olympus）
• Erbe Elektromedizin
• Chiesi Farmaceutici
• Mylan（Viatris）
• Cipla Ltd.
• Sun Pharmaceutical

結論與建議

Global Emphysema Treatment Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 8.99 Billion in 2025 to USD 13.85 Billion by 2033, growing at a CAGR of 5.52% during the forecast period (2026-2033).

The global emphysema treatment market is characterized by a range of pharmaceuticals, biologics, and device therapies designed to alleviate airflow obstruction and preserve lung function. The growing incidence of chronic obstructive pulmonary disease, coupled with an aging population and increased focus on respiratory health, is driving demand for effective treatments. The evolution from basic bronchodilators to advanced long-acting muscarinic antagonists and biologics reflects significant clinical progress, consistently enhancing symptom management and facilitating broader insurance coverage. Additionally, the rise of digital health platforms for monitoring patient adherence and pulmonary function is reshaping the industry by enabling timely interventions that reduce hospitalizations and lower overall healthcare costs. Strategic partnerships between device manufacturers and telemedicine providers are further fueling innovation and opening new revenue opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Emphysema Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Emphysema Treatment Market Segments Analysis

Global emphysema treatment market is segmented by treatment type, severity, distribution, end-user and region. Based on treatment type, the market is segmented into bronchodilators, corticosteroids, endobronchial valves, lung volume reduction surgery and oxygen therapy. Based on severity, the market is segmented into mild-moderate and severe. Based on distribution, the market is segmented into hospital pharmacies and retail pharmacies. Based on end-user, the market is segmented into pulmonology clinics and hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Emphysema Treatment Market

The expansion of the global emphysema treatment market is significantly driven by enhanced public education initiatives and outreach programs by healthcare professionals, which have led to improved early detection of the disease. This increased awareness motivates both patients and caregivers to pursue timely therapeutic options, thereby driving demand for effective treatments aimed at improving life quality and slowing disease advancement. Consequently, healthcare providers are more inclined to invest in innovative drug delivery systems and supportive services that focus on patient-centric care. Additionally, the influence of patient advocacy organizations is prompting the integration of advanced therapies that address unmet clinical needs and optimize health outcomes.

Restraints in the Global Emphysema Treatment Market

The elevated costs linked to advanced biologics, innovative drug delivery systems, and extensive care programs create a notable financial challenge for patients, insurers, and healthcare facilities. Often, inadequate reimbursement structures result in postponed treatment initiation or outright denials, hindering market demand and discouraging the acceptance of cutting-edge solutions, particularly in areas with limited healthcare resources or where out-of-pocket costs pose a significant burden to vulnerable groups. This situation ultimately impedes overall market expansion. Furthermore, cost-effectiveness evaluations tend to favor well-established generic alternatives, further restricting the market potential for premium treatment options aimed at managing emphysema.

Market Trends of the Global Emphysema Treatment Market

The Global Emphysema Treatment market is witnessing a notable trend towards personalized therapy, as healthcare providers increasingly customize treatment plans to suit individual patient phenotypes through advanced imaging and genetic profiling techniques. This approach enhances the precision of bronchoscopic interventions and pharmacotherapy, leading to improved treatment outcomes and a decrease in adverse effects. A growing focus on multidisciplinary care pathways that bring together pulmonology, radiology, and rehabilitation fosters collaborative decision-making among clinicians. Simultaneously, as reimbursement models shift towards outcome-based frameworks, hospitals are investing in necessary training and technology, driving demand for innovative, patient-centric solutions across both established and emerging markets.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Emphysema Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Bronchodilators
• Corticosteroids
• Endobronchial Valves
• Lung Volume Reduction Surgery
• Oxygen Therapy

Global Emphysema Treatment Market Size by Severity & CAGR (2026-2033)

• Market Overview
• Mild-Moderate
• Severe

Global Emphysema Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies

Global Emphysema Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Pulmonology Clinics
• Hospitals

Global Emphysema Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Severity, Distribution, End-User)
  • US
  • Canada
• Europe (Treatment Type, Severity, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Severity, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Severity, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Severity, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (Symbicort)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Spiriva)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PulmonX Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (Spiration Valve)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BTG plc (Boston Scientific)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Uptake Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Broncus Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nuvaira Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSA Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spiration (Olympus)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Erbe Elektromedizin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi Farmaceutici
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations